- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01877863
The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients
March 19, 2014 updated by: Dr Jennifer MacRae, University of Calgary
The purpose of this study is to explore the impact of an intradialytic exercise program on functional capacity, aerobic capacity, strength, quality of life, depression, hospitalizations and intradialytic episodes of hypotension.
The investigators would also like to look at the impact of exercise training over twelve weeks on hemoglobin levels as well as the clearance of potassium, phosphate and urea.
Our hypothesis is that the above mentioned outcomes will positively improve over the twelve week intervention.
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2L 2J8
- Northwest Dialysis Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cardiac and hemodynamic stability
- Absence of severe musculoskeletal impairment
- Increased musculoskeletal weakness
- Vital signs within normal range for exercise
- Desire/motivated to exercise
- Clearance from nephrologist and Kinesiologist
Exclusion Criteria:
- Compromised cardiac profiles
- Hemodynamic instability
- Severe bone disease
- Medical conditions which contraindicate exercise
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: intradialytic exercise
baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
|
12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Capacity
Time Frame: 12 weeks
|
Functional capacity is measured by the DASI score which gives an estimated V02 peak in ml/min/kg.
The difference between the mean score at baseline and 12 weeks will be determined.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aerobic capacity
Time Frame: 12 weeks
|
Aerobic capacity is measured as a function of the DASI score
|
12 weeks
|
|
Strength
Time Frame: 12 weeks
|
Strength is determined as bilateral hand grip strength (measured in kg) as well as by the 30 second sit to stand test(the number of repetitions achieved in 30 seconds).
These measures are obtained at baseline and again at 12 weeks.
|
12 weeks
|
|
Quality of life
Time Frame: 12 weeks
|
The KDQOL- SF36 will be used to measure the quality of life at baseline and again at 12 weeks.
|
12 weeks
|
|
Hospitalizations
Time Frame: 12 weeks
|
The number and rate of hospitalizations will be determined prior to exercise start and during the 12 week exercise program.
Length of stay is also tracked.
|
12 weeks
|
|
Hypotension
Time Frame: 12 weeks
|
Intradialytic hypotension, defined as a drop in systolic blood pressure (SBP) of 20 mmHg for patients with pre-dialysis blood pressure > 100 mmHg or a drop in SBP of 10 mmHg for patients with pre-dialysis blood pressure < = 90 mmHg.
IDH with patient symptoms and nursing interventions will be obtained as well.
|
12 weeks
|
|
Hemoglobin levels
Time Frame: 12 weeks
|
The baseline hemoglobin and hemoglobin at 12 weeks will be tracked.
|
12 weeks
|
|
Potassium levels
Time Frame: 12 weeks
|
The baseline potassium and potassium at 12 weeks as well as the K gradient (pre -dialysis - dialysate K level)will be monitored.
|
12 weeks
|
|
Urea removal
Time Frame: 12 weeks
|
The baseline and 12 week pre and post dialysis urea levels will be monitored.
|
12 weeks
|
|
Phosphate levels
Time Frame: 12 weeks
|
The baseline and 12 week pre-dialysis phosphate levels will be tracked.
|
12 weeks
|
|
Bioimpedance derived volume and body mass determinations
Time Frame: 12 weeks
|
In a small subset of patients (n=10) the bioimpedance derived fluid compartments (ECF, ICF, E:I ratio) and fat free body mass will be determined at both baseline and 12 weeks.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jennifer MacRae, University of Calgary
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
May 27, 2013
First Submitted That Met QC Criteria
June 13, 2013
First Posted (Estimate)
June 14, 2013
Study Record Updates
Last Update Posted (Estimate)
March 20, 2014
Last Update Submitted That Met QC Criteria
March 19, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-25253
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Kidney Disease
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
University of WashingtonCompleted
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
AbbottTerminatedEnd-Stage Kidney DiseaseUnited States
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedEnd-stage Kidney DiseaseUnited States
-
Ewha Womans UniversityUnknownEnd-Stage Kidney Disease
-
University of ChicagoCompletedEnd-Stage Kidney DiseaseUnited States
-
Sahlgrenska University Hospital, SwedenNot yet recruiting
Clinical Trials on exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
University of Missouri-ColumbiaCompleted
-
University of AlcalaCompletedMyofascial Pain | Myofascial Pain Syndrome | Post Needling Soreness | Myofascial Trigger Point PainSpain
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Bayero University Kano, NigeriaCompletedChronic Low Back PainNigeria
-
University College CorkRecruitingDepressive Disorder, MajorIreland